Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 6Leukemia 5Neoplasms by Histologic Type 4Myeloproliferative Disorders 4Leukemia, Myeloid 4Hematologic Diseases 4Carcinoma, Non-Small-Cell Lung 4Bone Marrow Diseases 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myeloid, Chronic-Phase 2Immunoproliferative Disorders 2Immune System Diseases 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Piebaldism 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Malignant Hepatobiliary Neoplasm 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Carcinoma, Squamous Cell 1Blast Crisis 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioblastoma × ponatinib × Clear all
NCT02478164 2018-07-24

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Completed
17 enrolled 13 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡